Research programme: osteoarthritis therapeutic - Transition Therapeutics
Alternative Names: TT-601Latest Information Update: 25 Apr 2014
At a glance
- Originator Eli Lilly and Company
- Class Small molecules
- Mechanism of Action Cytoplasmic and nuclear receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Osteoarthritis
Most Recent Events
- 07 Apr 2014 Discontinued - Preclinical for Osteoarthritis in USA (unspecified route)
- 23 Jul 2013 Preclinical trials in Osteoarthritis in USA (unspecified route)